Lorenzini, M;
Elliott, PM;
(2019)
Tafamidis for the treatment of transthyretin amyloidosis.
Future Cardiology
, 15
(2)
pp. 53-61.
10.2217/fca-2018-0078.
Preview |
Text
Elliot_CombinedAAM.pdf - Accepted Version Download (550kB) | Preview |
Abstract
Transthyretin (TTR) related cardiomyopathy is an underdiagnosed cause of heart failure but is increasingly recognized in various settings - from patients admitted with heart failure to symptomatic aortic stenosis - and is rapidly becoming the most frequent form of systemic amyloidosis. Following the recent publication of the landmark ATTR-ACT trial that showed tafamidis to be the first treatment to improve survival in patients with TTR-related cardiac amyloidosis and heart failure, we reviewed the drug's rationale, characteristics and evidence supporting its use in TTR amyloidosis.
| Type: | Article |
|---|---|
| Title: | Tafamidis for the treatment of transthyretin amyloidosis |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.2217/fca-2018-0078 |
| Publisher version: | https://doi.org/10.2217/fca-2018-0078 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | amyloidosis, cardiomyopathy, tafamidis, transthyretin |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science > Clinical Science |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10069107 |
Archive Staff Only
 |
View Item |
